WIPO has published 2 studies on inventive step and sufficiency of disclosure in patent laws.
Yates J has upheld the Registrar’s refusal to register SIR WALTER for buffalo grass in class 31 on the grounds it lacked any capacity to distinguish and was not in fact distinctive.
ACIP now recommends abolition of the innovation patent system
Having had the interlocutory injunction he granted overturned on appeal, Rares J has now determined at the substantive trial that both of Glaxo’s syringe variants infringed Reckitt Benkiser’s “flat-nosed syringe” patent.
Nicholas J has granted Thomas International an interlocutory injunction ordering Humantech to transfer the domain names, thomasinternational.com.au and thomas.co.za, to Thomas International. Thomas International had to give the usual undertakings and, as a foreign corporation, provide security for costs.
Perram J has reluctantly found that actual control of the licensee is not necessary and potential control will suffice for authorised use under the Trade Marks Act 1995.
The Full Court has partially allowed Tamawood’s appeal, and denied Habitare’s appeal from Collier J’s findings about copyright infringement.
The Full Federal Court has allowed the Commissioner of Taxation’s appeal from Pagone J’s ruling allowing SPI Powernet a deduction for the value of its copyright in the plans, drawings and manuals for its electricity power generation network.
ACIP’s final report into its review of the Designs System has been published. The report is 70 pages (including annexes) – 43 pages for the report itself; and 23 recommendations. Key recommendations include: investigate joining the Hague system and, if a decision is made to join, extend the maximum term of design protection to 15 years; introduce a grace period of 6 months before the filing date, but require an.. Read More
Sanofi sued Apotex (then known as GenRx) for infringement of its “clopidogrel patent”. It obtained interlocutory injunctions against Apotex against the sale of Apotex’ product and preventing Apotex from applying to list its product under the Pharmaceutical Benefits scheme (PBS). As a condition of the grant of those interlocutory injunctions, Sanofi gave the “usual undertaking as to damages”: “(a) submit to such order (if any) as the Court may consider to.. Read More